The Rheumatology Network lupus clinical focus page provides information on the latest lupus news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for systemic lupus erythematosus drugs.
May 09, 2022
After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.
May 05, 2022
The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.
April 25, 2022
Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.
April 22, 2022
Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.
April 21, 2022
Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.
April 21, 2022
Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.
April 20, 2022
Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.
April 19, 2022
Disease flares in systemic lupus erythematosus are associated with damage. However, the impact of flares on health-related quality of life have not been analyzed.
April 06, 2022
Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.
March 24, 2022
Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.